Gadodiamide hydrate |
رقم الكتالوجGC17611 |
Gadodiamide هو عامل تباين قائم على الجادولينيوم يستخدم في إجراءات التصوير بالرنين المغناطيسي للمساعدة في تصور الأوعية الدموية.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 122795-43-1
Sample solution is provided at 25 µL, 10mM.
Gadodiamide hydrate is a gadolinium-based contrast agent used in MR imaging procedures to assist in the visualization of blood vessels. Target: OthersGadodiamide hydrate is a gadolinium-based contrast agent used in MR imaging procedures to assist in the visualization of blood vessels. Gadodiamide hydrate is a contrast medium for cranial and spinal magnetic resonance imaging (MRI) and for general MRI of the body after intravenous administration. The product provides contrast enhancement and facilitates visualisation of abnormal structures or lesions in various parts of the body including the central nervous system (CNS). A recent review takes the question of toxicity caused by loss of gadolinium from the complex. "The challenge for nephrologists includes (a) evidence of transmetallation, such as gadolinium deposits in bone, increased urinary zinc excretion, iron-transferrin dissociation or 'spurious hypocalcemia' in exposed people" [1].
References:
[1]. Canavese, C., et al., Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness. J Nephrol, 2008. 21(3): p. 324-36.
Animal experiment [1]: | |
Animal models |
Rats or monkeys |
Dosage form |
0.25 ~ 10 mmol/kg; i.v |
Applications |
In rats, a single dose of Gadodiamide at a greater than 0.5 mmol/kg induced vacuolization of the proximal tubular cells in kidneys, without affecting renal function. At a dose up to 10 mmol/kg, the vacuolization was only at the moderate degree, and was shown to regress partially during the 7 days after administration. In monkeys, administration of 0.25 mmol/kg Gadodiamide (q.d.; for 28 days) exhibited no effect on the kidneys. |
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. Harpur ES, Worah D, Hals PA, Holtz E, Furuhama K, Nomura H. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest Radiol. 1993 Mar;28 Suppl 1:S28-43. |
Cas No. | 122795-43-1 | SDF | |
Chemical Name | 2-[bis[2-[carboxylatomethyl-[2-(methylamino)-2-oxoethyl]amino]ethyl]amino]acetate;gadolinium(3+);hydrate | ||
Canonical SMILES | CNC(=O)CN(CCN(CCN(CC(=O)NC)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].O.[Gd+3] | ||
Formula | C16H28GdN5O9 | M.Wt | 591.67 |
الذوبان | ≥ 29.2mg/mL in Water | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 1.6901 mL | 8.4507 mL | 16.9013 mL |
5 mM | 0.338 mL | 1.6901 mL | 3.3803 mL |
10 mM | 0.169 mL | 0.8451 mL | 1.6901 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5
(Based on Reviews and 37 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *